Table 1.
Displays information on the 240 serum samples used during RPPA analysis.
Fig 1.
Copy number alteration and survival data.
A. Illustrates percentage of VTN gene altered in a sample of 881 tumor specimens from CCLE database. Across, all cancer cell lines, only 3% of the VTN is altered by either amplification or deletion of the gene, however, the BC cell lines have a high percentage of VTN copy number amplified. B. Data illustrates the percentage of BC tumor specimens that have their VTN copy number amplified in a sample of 2173 BC patients from the METABRIC database. About 5% of these patients had their VTN copy number amplified. C. Data indicates the survival rates of BC patients with and without the alteration (CNA, amplification) to the VTN gene from the same study seen in B.
Table 2.
Displays mean fold change and standard error (SE) from the RPPA dataset, comparing race and tumor subtypes to the control group.
Data allows us to compare level of vitronectin in serum. The mean fold change is relative to the control population for the same ethnicity.
Fig 2.
Serum concentration levels of vitronectin in patient samples from RPPA.
A. Image displays the RPPA dot blot which was stained with the vitronectin antibody. Intensity values were taken from here and then analyzed. B-F. Displays comparisons of mean relative values of each group using standard error for error bars. B. analyzes overall serum vitronectin levels in control group (n = 40) and cancer group (n = 200). C. analyzes serum vitronectin levels (overall) in control groups and compared with the other tumor subtypes. Her2+ and LB2 show significant differences when compared to control group. D. compares control and cancer groups by ethnicity, and we find that CA cancer shows a significantly higher vitronectin concentration levels. E. we see that it compares vitronectin levels of AA and WA patients by dividing into various tumor characteristics. However, we found that there are significant differences in Her2+ and LB2 subtypes in the AA group when compared to AA controls. F. compares recurrent versus non-recurrent patient samples by ethnic groups. We found that there is a significant difference in serum vitronectin levels in non-recurrent CA compared to the control and recurrent groups, while AA samples had similar levels of serum vitronectin in all three groups.
Fig 3.
Validation of RPPA data and assessment of racial disparities in serum concentration levels of vitronectin in Her2+ and LB2 tumor subtypes.
The data above is validation of data shown in Fig 2, that showed potential racial disparities in tumor subtypes in vitronectin concentration levels of serum. A. Displays the relative concentration levels of vitronectin in AA Her2+ patients in serum compared with corresponding control samples. B. Relative serum concentration levels of vitronectin in WA Her2+ patients and compared with healthy patients C. Displays the relative serum concentration levels of vitronectin in AA LB2 patients and control serum. D. Displays the relative concentration levels of vitronectin in CA LB2 patients in serum.
Fig 4.
Recurrence and vitronection concentration level in serum.
A. Overall concentration level of vitronectin in 21 recurrence samples (n = 21) and compared serum vitronectin concentration levels to 21 non-recurrence samples of same IHC sub-groups. B. Receiver Operation Characteristic (ROC) Curve and, the statistical evaluation of vitronectin concentration in serum samples between non-recurrence vs recurrence patients. We tested to see if vitronectin could be used as a recurrence biomarkers and, we found that the area under curve (AUC) is 0.7107 with a p-value 0.0940.
Fig 5.
Vitronectin expression is modulated by PI3K/AKT axis.
A. Displays the pseudo blot extracted from SimpleWestern experiments. There are four cell-lines- MDA-MB-231, MCF7, MDA-MB-468, HCC1599, were used to evaluate the signaling cascade relationship. Different protein expression levels were normalized with an averaged house-keeping GAPDH and β-actin expression B. Compares vitronectin concentration levels in four BC cell lines. C. PI3K concentration levels in BC same cell-lines. D. compares AKT concentration and, E. P-AKT concentration levels in the same four BC cell lines.